Xenon Pharmaceuticals Inc. cash flow to debt ratio of -3.51K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Xenon Pharmaceuticals Inc.'s free cash flow has decreased 51.75% from $-184.46M last year to $-279.92M, signaling decreasing performance

Xenon Pharmaceuticals Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Xenon Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

Xenon Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Xenon Pharmaceuticals Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Xenon Pharmaceuticals Inc. has insufficient data to evaluate this check.

Xenon Pharmaceuticals Inc.'s short-term assets of $560.65M exceed its short-term liabilities of $41.79M

Xenon Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Xenon Pharmaceuticals Inc.'s return on equity of -43.98%, is lower than 15.00%, indicating bad performance

Xenon Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Xenon Pharmaceuticals Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Xenon Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Xenon Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Xenon Pharmaceuticals Inc.'s yearly earnings has decreased 47.62% since last year from $-234.33M to $-345.91M, signaling decreasing performance

Xenon Pharmaceuticals Inc.'s yearly revenue has increased % since last year from $0.00 to $7.50M, signaling increasing performance

ROIC -35.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Xenon Pharmaceuticals Inc.'s 3-year revenue CAGR of -7.36% is negative, indicating declining revenue over the past 3 years

Xenon Pharmaceuticals Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Xenon Pharmaceuticals Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Xenon Pharmaceuticals Inc. has insufficient data to evaluate this check.

Xenon Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Xenon Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Xenon Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Xenon Pharmaceuticals Inc. is overvalued relative to its fair value price of -8.70 based on Earnings Fair Value model

Xenon Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Xenon Pharmaceuticals Inc. has a price-to-book ratio of 5.15x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Xenon Pharmaceuticals Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue